Charter Hall Long WALE Stock (OTC: CHLWF)

Latest news for Charter Hall Long WALE (OTC:CHLWF) Stock

Charter Hall Long Wale REIT is a diversified property trust with assets across Australia and New Zealand. It boasts nearly full occupancy and long average lease durations. Over half of its leases are triple-net, where tenants cover most operating expenses. The REIT's extensive portfolio includes offices, industrial, retail, social infrastructure, and agricultural logistics, with the majority located on Australia's eastern seaboard.

Stapled Secs Cons of 1 DIF + 1 FSPT + 1 Finance Tr

Charter Hall Long WALE REIT Stapled Secs Cons of 1 DIF + 1 FSPT + 1 Finance Tr

Charter Hall Long WALE REIT

MetaVia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>),&nbsp;a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate as a Sponsor and Exhibitor at the upcoming, 9th Annual MASH-TAG 2025 Conference. The company's participation follows the recent release of positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The MASH-TAG Conference is taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah. Members of MetaVia's management and clinical team will be available in the Exhibit Hall at the Conference to discuss the results of the Phase 2a clinical trial of DA-1241.

Biotech

News

General

MTVA

MetaVia Releases Top-Line Results From Its Phase 2a Clinical Trial Of DA-1241 In Patients With Presumed MASH At The 9th Annual MASH-TAG 2025 Conference

MRKR

Marker Therapeutics Secures $16.1M In Private Placement To Advance Phase 1 APOLLO Study Of MT-601 T Cell Therapy For Lymphoma Patients Relapsed After Anti-CD19 CAR-T Treatment

WIIM

SHCO

Soho House shares are trading higher after the company received a $9.00 per share acquisition offer from a consortium backed by Executive Chairman Ron Burkle and Yucaipa. The board has formed a special committee to evaluate the proposal.

QNRX

Quoin Pharmaceuticals shares are trading higher after the company announced it received FDA clearance to initiate a new QRX003 Netherton Syndrome clinical study.

IMNN

IMUNON Announces FDA Alignment On CMC Strategy For IMNN-001 In Advanced Ovarian Cancer, Phase 3 Trial Set To Begin Q1 2025 With cGMP Manufacturing Process And Potency Assay Approved For Clinical And Commercial Use

reAlpha Tech Corp. ("reAlpha" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>), a real estate technology company developing and commercializing artificial intelligence ("AI") technologies, today announced that its board of directors has approved an investment policy for the purchase of cryptocurrencies and to adopt Bitcoin, Ethereum and Solana (collectively, the "cryptocurrencies") as reAlpha's primary treasury reserve assets. The Company plans to allocate up to 25% of its cash in excess of its estimated 6-month period operating expenses, if any, towards cryptocurrency purchases, subject to market conditions and actual operating needs of the Company, reflecting the Company's commitment to innovative capital management and diversification strategies.
Cryptocurrencies are recognized as a decentralized store of value, and the decision to adopt cryptocurrencies as reAlpha's primary treasury reserve assets is part of its strategy to diversify its treasury holdings, which is currently only comprised of cash.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

AIRE

reAlpha Plans To Allocate Up To 25% Of Excess Cash To Cryptocurrency Purchases And To Adopt Bitcoin, Ethereum And Solana

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $3 price target.

Price Target

Reiteration

Analyst Ratings

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $3 Price Target

AQST

Aquestive Therapeutics Secures FDA Orphan Drug Exclusivity For Libervant Buccal Film In Pediatric Seizure Clusters Ages 2 To 5, Highlighting Major Care Advancement With Buccal Administration Over Rectal Route

CLDX

Celldex Launches Phase 2 Study Of Barzolvolimab For Atopic Dermatitis, Targeting Mast Cell-Driven Inflammation And Epithelial Barrier Dysfunction With Patient Enrollment Underway

NVEE

NV5 Secures $7M In Infrastructure Design Contracts From City Of Philadelphia To Enhance Green Infrastructure, Safety, And Sustainability With Projects Set For Completion By 2028

<ul>
<li>The 2024 Canadian Headache Society (CHS) Migraine Prevention Guideline, which replaces the previous version published in 2012, granted strong recommendations for atogepant in episodic and chronic migraine, and for onabotulinumtoxinA in chronic migraine.1</li>
<li>The new CHS Migraine Prevention Guideline is based on a comprehensive systematic review and meta-analysis and addresses both episodic and chronic migraine.1</li>
<li>A strong recommendation was issued when an intervention was deemed suitable for the majority of patients, with benefits outweighing potential risks.1</li>
</ul>
MONTRÉAL, Dec. 19, 2024 /CNW/ - AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)&nbsp;announced today that atogepant and onabotulinumtoxinA&nbsp;have received strong recommendations in the newly updated <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4328408-1&amp;h=3973992059&amp;u=https%3A%2F%2Fwww.headachesociety.ca%2F_files%2Fugd%2F9f0189_8eb9049b4b1943268725ebf41088ea0c.pdf&amp;a=CHS+Migraine+Prevention+Guideline">CHS Migraine Prevention Guideline</a>: atogepant is strongly recommended in the treatment of episodic and chronic migraine, and onabotulinumtoxinA, in the treatment of chronic migraine (please refer to the guideline for the full recommendations). The 2024 version marks a crucial step forward in equipping healthcare professionals with the most current, evidence-based recommendations for preventing and managing migraines – a condition that impacts millions of Canadians.2

ABBV

AbbVie's Atogepant And OnabotulinumtoxinA Receive Strong Recommendations In The Newly Updated Canadian Headache Society Migraine Prevention Guideline; A Strong Recommendation Was Issued When An Intervention Was Deemed Suitable For The Majority Of Patients, With Benefits Outweighing Potential Risks

Soho House Receives $9.00 Per Share Acquisition Offer From Third-Party Consortium Backed By Executive Chairman Ron Burkle And Yucaipa, Representing An 83% Premium, With Board Forming Special Committee To Evaluate Proposal

Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX&#xAE; System powered by Nano-Pulse Stimulation&#x2122; (NPS&#x2122;) technology, today announced that, on December 18, 2024, the Company's Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants he acquired in the Company's 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of Company common stock. Mr. Duggan also confirmed that, from December 11, 2024 through this past Friday, December 13, 2024, he has purchased an additional 156,714 shares of Pulse Biosciences. These transactions bring Mr. Duggan's current ownership in the Company to approximately 70%.

Offerings

PLSE

Pulse Biosciences,, On December 18, 2024, The Co's Co-Chairman And Majority Shareholder, Robert W. Duggan, Exercised All Of The Warrants He Acquired In The Co's 2024 Rights Offering, Corresponding To $58.4M Totaling To 5,306,156 Shares Of Company Common Stock

PTCT

PTC Therapeutics Submits NDA To FDA For Vatiquinone As Potential First Approved Therapy For Friedreich Ataxia In Children And Adults, Marking Fourth FDA Application In 2024

Telsey Advisory Group analyst Cristina Fernandez upgrades RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from Market Perform to Outperform and raises the price target from $485 to $500.

Upgrades

Telsey Advisory Group Upgrades RH to Outperform, Raises Price Target to $500

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">231.58</td>
<td align="right">2.94</td>
<td align="right">1.28</td>
<td>6.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">98.71</td>
<td align="right">1.01</td>
<td align="right">1.03</td>
<td>230</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">234.33</td>
<td align="right">2.09</td>
<td align="right">0.89</td>
<td>24.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">48.01</td>
<td align="right">0.38</td>
<td align="right">0.79</td>
<td>363.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">84.64</td>
<td align="right">0.59</td>
<td align="right">0.70</td>
<td>14.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">133.35</td>
<td align="right">0.91</td>
<td align="right">0.68</td>
<td>1.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.00</td>
<td align="right">0.24</td>
<td align="right">0.58</td>
<td>5.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.42</td>
<td align="right">0.19</td>
<td align="right">0.23</td>
<td>10.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">75.05</td>
<td align="right">0.16</td>
<td align="right">0.21</td>
<td>9.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">137.54</td>
<td align="right">0.22</td>
<td align="right">0.16</td>
<td>14.3K</td>
</tr>
</tbody>
</table>
No loser in today's Pre-market session. 
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For December 19, 2024

PLUR

Pluri Applauds Mesoblast For FDA Approval Of First Mesenchymal Stromal Cell Therapy For Steroid-Refractory Acute Graft-Versus-Host Disease, Highlighting Regenerative Medicine's Transformative Potential And Advancing MSC Therapies In Healthcare

- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer -
- Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 -
CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board. The advisory board, which comprises world-renowned oncology clinical researchers, will provide strategic medical and clinical guidance to the company as its pipeline, including lead clinical program IMM-1-104, continues to advance.

Management

IMRX

Immuneering Launches Pancreatic Cancer Advisory Board; Establishment Reflects The Clinical Progress Of IMM-1-104 And Its Promise In Pancreatic Cancer

WestPark Capital analyst Casey Ryan initiates coverage on Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) with a Buy rating and announces Price Target of $1.3.

Initiation

MVIS

WestPark Capital Initiates Coverage On Microvision with Buy Rating, Announces Price Target of $1.3

CarMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) shares are trading higher after the company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42572355/carmax-reports-third-quarter-fiscal-year-2025-results" rel="noreferrer noopener">third-quarter earnings results</a>.
Quarterly sales of&nbsp;$6.223 billion&nbsp;beat the street view of&nbsp;$6.042 billion. The company reported earnings per share of 81 cents, beating the&nbsp;analyst <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus estimate of 64 cents</a>.
CarMax Auto Finance income was&nbsp;$159.9&nbsp;million, an increase of 7.6%&nbsp;year over year, driven by an improvement in CAF&#8217;s net interest margin percentage and higher average managed receivables.
The provision for loan losses was consistent with expectations set at the end of the second quarter of this year.
Retail used unit sales rose by&nbsp;5.4% Y/Y, comparable store used unit sales increased by&nbsp;4.3%&nbsp;Y/Y and wholesale units increased&nbsp;6.3% Y/Y.
Gross profit per retail used unit was&nbsp;$2,306 (flat Y/Y), and gross profit per wholesale unit was&nbsp;$1,015 (up $54 per unit Y/Y). The Extended Protection Plan margin increased by&nbsp;$53&nbsp;per retail unit to&nbsp;$573.
In the third quarter of fiscal year 2025, the company repurchased 1.5 million shares of common stock for $114.8 million. As of November 30, 2024, the company had $2.04 billion remaining available for repurchase under the outstanding authorization.
The company exited the quarter with cash and equivalents worth&nbsp;$271.9 million. Restricted cash from collections on auto loans receivable totaled $541.15 million. Inventories at quarter-end was&nbsp;$3.665 billion.
Bill Nash, president and chief executive officer, said, &#8221;Our solid execution and a more stable environment for vehicle valuations enabled us to deliver robust EPS growth driven by increases in unit sales and buys, solid margins, growth in CAF income, and ongoing management of SG&amp;A.&#8221;&nbsp;
During the&nbsp;third quarter&nbsp;of fiscal 2025, the company opened one new store in Alliance, Texas.
Investors can gain exposure to the stock via Valued Advisers Trust Kovitz Core Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQTY#NYSE">EQTY</a>) and Invesco Bloomberg Analyst Rating Improvers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPGD#NYSE">UPGD</a>).
Price Action: KMX shares are trading higher by 6.44% to $86.66 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42569970/carmax-gears-up-for-q3-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts" target="_blank" rel="noreferrer noopener">CarMax Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock.

Comments

Charter Hall Long WALE

News

Latest news for Charter Hall Long WALE (OTC:CHLWF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga